The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018

Carolien C.H.M. Maas; David van Klaveren; Geneviève I.C.G. Ector; Eduardus F.M. Posthuma; Otto Visser; Peter E. Westerweel; Jeroen J.W.M. Janssen; Nicole M.A. Blijlevens; Avinash G. Dinmohamed

doi:10.1111/bjh.17989

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018

Carolien C.H.M. Maas
, David van Klaveren
, Geneviève I.C.G. Ector
, Eduardus F.M. Posthuma
, Otto Visser
, Peter E. Westerweel
, Jeroen J.W.M. Janssen
, Nicole M.A. Blijlevens
, Avinash G. Dinmohamed^*

^*Corresponding author for this work

Radboud University Medical Center
Reinier de Graaf Groep
Leiden University Medical Centre
VU University Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Scopus)

100 Downloads (Pure)

Abstract

Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.

Original language	English
Pages (from-to)	1219-1224
Number of pages	6
Journal	British Journal of Haematology
Volume	196
Issue number	5
DOIs	https://doi.org/10.1111/bjh.17989
Publication status	Published - Mar 2022

Bibliographical note

Acknowledgements:
The authors would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation (IKNL).

Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/bjh.17989Licence: CC BY-NC-ND

Br_J_Haematol_2021_Maas_The_evolution_of_the_loss_of_life_expectancy_in_patients_with_chronic_myeloid_leukaemia_aFinal published version, 721 KBLicence: CC BY-NC-ND

Cite this

Maas, C. C. H. M., van Klaveren, D., Ector, G. I. C. G., Posthuma, E. F. M., Visser, O., Westerweel, P. E., Janssen, J. J. W. M., Blijlevens, N. M. A., & Dinmohamed, A. G. (2022). The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018. British Journal of Haematology, 196(5), 1219-1224. https://doi.org/10.1111/bjh.17989

@article{5a722aba1b034677b08a7d673665378e,

title = "The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989{\textendash}2018",

abstract = "Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989{\textendash}2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population{\textquoteright}s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.",

author = "Maas, \{Carolien C.H.M.\} and \{van Klaveren\}, David and Ector, \{Genevi{\`e}ve I.C.G.\} and Posthuma, \{Eduardus F.M.\} and Otto Visser and Westerweel, \{Peter E.\} and Janssen, \{Jeroen J.W.M.\} and Blijlevens, \{Nicole M.A.\} and Dinmohamed, \{Avinash G.\}",

note = "Acknowledgements: The authors would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation (IKNL). Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2022",

month = mar,

doi = "10.1111/bjh.17989",

language = "English",

volume = "196",

pages = "1219--1224",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "5",

}

Maas, CCHM , van Klaveren, D, Ector, GICG, Posthuma, EFM, Visser, O, Westerweel, PE, Janssen, JJWM, Blijlevens, NMA & Dinmohamed, AG 2022, 'The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018', British Journal of Haematology, vol. 196, no. 5, pp. 1219-1224. https://doi.org/10.1111/bjh.17989

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018. / Maas, Carolien C.H.M.; van Klaveren, David; Ector, Geneviève I.C.G. et al.
In: British Journal of Haematology, Vol. 196, No. 5, 03.2022, p. 1219-1224.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia

T2 - a population-based study in the Netherlands, 1989–2018

AU - Maas, Carolien C.H.M.

AU - van Klaveren, David

AU - Ector, Geneviève I.C.G.

AU - Posthuma, Eduardus F.M.

AU - Visser, Otto

AU - Westerweel, Peter E.

AU - Janssen, Jeroen J.W.M.

AU - Blijlevens, Nicole M.A.

AU - Dinmohamed, Avinash G.

N1 - Acknowledgements: The authors would like to thank the registration clerks of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation (IKNL). Publisher Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2022/3

Y1 - 2022/3

N2 - Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.

AB - Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.

UR - https://www.scopus.com/pages/publications/85120468512

U2 - 10.1111/bjh.17989

DO - 10.1111/bjh.17989

M3 - Article

C2 - 34865221

AN - SCOPUS:85120468512

SN - 0007-1048

VL - 196

SP - 1219

EP - 1224

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989–2018

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this